Results 21 to 30 of about 42,229 (197)

Accelerated in vivo proliferation of memory phenotype CD4+ T-cells in human HIV-1 infection irrespective of viral chemokine co-receptor tropism. [PDF]

, 2013
CD4(+) T-cell loss is the hallmark of HIV-1 infection. CD4 counts fall more rapidly in advanced disease when CCR5-tropic viral strains tend to be replaced by X4-tropic viruses.
A Kaur, A Llano, A Yates, AN Phillips, Andrea Hegedus, Andrew Worth, B Asquith, Catherine de Lara, D Berhanu, Daniel C. Douek, DC Douek, DC Douek, DC Macallan, DC Macallan, DC Macallan, DC Macallan, DD Ho, Derek Macallan, DL Wallace, EJ Heeregrave, HC Lane, I den Braber, J Embretson, JM Brenchley, JM McCune, JV Giorgi, K Ladell, Karoliina Laamanen, L Cicin-Sain, LJ Picker, M Catalfamo, M Hellerstein, M Koot, MD Hazenberg, MK Hellerstein, MP Davenport, N Brieu, N Vrisekoop, Peter Beverley, R Busch, R Shankarappa, RJ De Boer, RJ De Boer, RM Ribeiro, RM Ribeiro, RS Veazey, SA Handley, TW Chun, V Sanchez, Yan Zhang   +49 more
core   +7 more sources

A genetic IFN/STAT1/FAS axis determines CD4 T stem cell memory levels and apoptosis in healthy controls and Adult T-cell Leukemia patients

OncoImmunology, 2018
Adult T-cell leukemia (ATL) is an aggressive, chemotherapy-resistant CD4+CD25+ leukemia caused by HTLV-1 infection, which usually develops in a minority of patients several decades after infection. IFN + AZT combination therapy has shown clinical benefit
Ricardo Khouri, Gilvanéia Silva-Santos, Tim Dierckx, Soraya Maria Menezes, Daniele Decanine, Kristof Theys, Aline Clara Silva, Lourdes Farré, Achiléa Bittencourt, Massimo Mangino, Mario Roederer, Anne-Mieke Vandamme, Johan Van Weyenbergh   +12 more
doaj   +1 more source

JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand. [PDF]

, 2009
Background: cJun terminal kinase (JNK) is constitutively activated in most hepatocellular carcinomas (HCCs), yet its exact role in carcinogenesis remains controversial.
Bruns, Christiane, Camaj, Peter, De Toni, Enrico, Eichhorst, Sören T., Gallmeier, Eike, Gerbes, Alexander L., Göke, Burkhard, Kolligs, Frank T., Mucha, Simon R., Rizzani, Antonia, Thasler, Wolfgang E.   +10 more
core   +1 more source

3D Cellular Architecture Modulates Tyrosine Kinase Activity, Thereby Switching CD95-Mediated Apoptosis to Survival

Cell Reports, 2019
Summary: The death receptor CD95 is expressed in every cancer cell, thus providing a promising tool to target cancer. Activation of CD95 can, however, lead to apoptosis or proliferation.
Gülce S. Gülcüler Balta, Cornelia Monzel, Susanne Kleber, Joel Beaudouin, Emre Balta, Thomas Kaindl, Si Chen, Liang Gao, Meinolf Thiemann, Christian R. Wirtz, Yvonne Samstag, Motomu Tanaka, Ana Martin-Villalba   +12 more
doaj   +1 more source

Analysis of novel meningococcal vaccine formulations

Human Vaccines & Immunotherapeutics, 2017
The protective effect of meningococcal vaccines targeting disease causing serogroups exemplified by the introduction of MenAfriVac™ in Africa, is well established and documented in large population-based studies.
Susu M. Zughaier
doaj   +1 more source

CD95 promotes tumour growth [PDF]

Nature, 2010
CD95 (also called Fas and APO-1) is a prototypical death receptor that regulates tissue homeostasis mainly in the immune system through the induction of apoptosis. During cancer progression CD95 is frequently downregulated or cells are rendered apoptosis resistant, raising the possibility that loss of CD95 is part of a mechanism for tumour evasion ...
Lina, Chen, Sun-Mi, Park, Alexei V, Tumanov, Annika, Hau, Kenjiro, Sawada, Christine, Feig, Jerrold R, Turner, Yang-Xin, Fu, Iris L, Romero, Ernst, Lengyel, Marcus E, Peter   +10 more
openaire   +2 more sources

APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo [PDF]

, 2011
Death receptor targeting has emerged as one of the promising novel approaches of cancer therapy. The activation of one such prototypic death receptor, CD95 (Fas/APO-1), has remained controversial because CD95 agonistic molecules have exhibited either too
Aulwurm, S, Eisele, G, Hasenbach, K, Roth, P, Tabatabai, G, Weller, M, Wick, W, Wolpert, F   +7 more
core   +1 more source

CD95 is part of a let-7/p53/miR-34 regulatory network. [PDF]

PLoS ONE, 2012
The death receptor CD95 (APO-1/Fas) mediates apoptosis induction upon ligation by its cognate ligand CD95L. Two types of CD95 signaling pathways have been identified, which are characterized by the absence (Type I) or presence (Type II) of mitochondrial ...
Annika Hau, Paolo Ceppi, Marcus E Peter
doaj   +1 more source

How CD95 stimulates invasion [PDF]

Cell Cycle, 2011
CD95 is best known for its capacity to induce apoptosis, but also activates multiple non-apoptotic signalling pathways. In particular, CD95 promotes migration and tissue invasion of apoptosis-resistant cell types, and this plays a central role in inflammation, neurobiology, and tumor biology.
Ernst J A, Steller, Inne H M, Borel Rinkes, Onno, Kranenburg   +2 more
openaire   +2 more sources

Pro- and anti-apoptotic CD95 signaling in T cells

Cell Communication and Signaling, 2011
The TNF receptor superfamily member CD95 (Fas, APO-1, TNFRSF6) is known as the prototypic death receptor in and outside the immune system. In fact, many mechanisms involved in apoptotic signaling cascades were solved by addressing consequences and ...
Janssen Ottmar, Paulsen Maren
doaj   +1 more source